Astellas, Seattle Genetics Break Ground With US ADC Approval
Earlier-Stage Combo Also Shows Big Promise
Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.
You may also be interested in...
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
Many Oncologic Drugs Advisory Committee members struggled to decide whether the data showed a clinically meaningful benefit in the proposed bladder cancer indication.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.